UK markets closed

ABIONYX Pharma SA (0RAG.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
1.8444-0.2041 (-9.97%)
At close: 05:41PM GMT
Currency in EUR

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 0.30
52-week change 3N/A
S&P500 52-week change 3-8.00%
52-week high 31.8712
52-week low 31.8444
50-day moving average 3N/A
200-day moving average 3N/A

Share statistics

Avg vol (3-month) 3N/A
Avg vol (10-day) 3N/A
Shares outstanding 518.22M
Implied shares outstanding 6N/A
Float 817.24M
% held by insiders 132.46%
% held by institutions 116.27%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 4N/A
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2021
Most-recent quarter (mrq)30 Jun 2022

Profitability

Profit margin -177.73%
Operating margin (ttm)-177.58%

Management effectiveness

Return on assets (ttm)-28.69%
Return on equity (ttm)-91.70%

Income statement

Revenue (ttm)3.28M
Revenue per share (ttm)0.12
Quarterly revenue growth (yoy)9,640.70%
Gross profit (ttm)259k
EBITDA -5.73M
Net income avi to common (ttm)-5.83M
Diluted EPS (ttm)-0.1480
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)4.03M
Total cash per share (mrq)0.14
Total debt (mrq)4.49M
Total debt/equity (mrq)51.98
Current ratio (mrq)1.67
Book value per share (mrq)0.31

Cash flow statement

Operating cash flow (ttm)-6M
Levered free cash flow (ttm)-4.47M